# NTRK1

## Overview
The NTRK1 gene encodes the neurotrophic receptor tyrosine kinase 1, commonly referred to as TrkA, which is a receptor tyrosine kinase integral to the signaling of nerve growth factor (NGF). This receptor is pivotal in the development and maintenance of the nervous system, particularly influencing the survival, differentiation, and function of specific neuronal populations. TrkA is categorized as a transmembrane receptor, featuring distinct structural domains that facilitate its role in signal transduction. Upon NGF binding, TrkA undergoes dimerization and autophosphorylation, activating downstream signaling pathways such as Ras/MAPK and PI3K, which are essential for cellular processes like proliferation and differentiation (Pierotti2006Oncogenic; Indo2001Molecular). Mutations in NTRK1 are linked to congenital insensitivity to pain with anhidrosis (CIPA), highlighting its clinical significance in sensory and autonomic nervous system disorders (Tüysüz2008Novel; Mardy1999Congenital).

## Structure
The NTRK1 gene encodes a receptor tyrosine kinase known as TrkA, which is crucial for nerve growth factor (NGF) signaling. The protein structure includes a signal peptide, an extracellular domain, a transmembrane domain, and an intracellular domain. The extracellular domain is responsible for NGF binding and features leucine-rich motifs, cysteine clusters, and immunoglobulin-like domains (Indo2001Molecular; Mardy2001Congenital). The intracellular domain contains a juxtamembrane region, a tyrosine kinase domain, and a C-terminal tail, which are essential for intracellular signaling and autophosphorylation (Pierotti2006Oncogenic; Mardy2001Congenital).

Upon NGF binding, NTRK1 undergoes dimerization and autophosphorylation at specific tyrosine residues, which serve as docking sites for downstream signaling molecules (Pierotti2006Oncogenic; Indo2001Molecular). This process activates signaling pathways such as Ras/MAPK and PI3K, influencing cellular processes like proliferation and differentiation (Pierotti2006Oncogenic).

Post-translational modifications include glycosylation and phosphorylation, which are critical for the protein's function and signaling capabilities (Martin-Zanca1989Molecular). Splice variants of NTRK1 can lead to different isoforms, potentially affecting its functional properties (Indo2001Molecular).

## Function
The NTRK1 gene encodes the neurotrophic receptor tyrosine kinase 1, also known as TrkA, which is a receptor for nerve growth factor (NGF). This receptor plays a crucial role in the development and function of the nervous system by promoting the survival, differentiation, and maintenance of specific neurons. NTRK1 is involved in several signal transduction pathways, including the mitogen-activated protein kinase (MAPK), phosphatidylinositol 3-kinase (PI3K), and PLC-g pathways, which lead to the activation of transcription factors that alter gene expression (Alberti2003RET). 

In healthy human cells, NTRK1 is expressed in neurogenic tissues and supports the survival and differentiation of sympathetic and sensory neurons, particularly those responsive to temperature and pain (Alberti2003RET). The receptor is primarily active in the cell membrane, where it influences processes such as axon guidance and pain perception. NTRK1 activation by NGF can inhibit angiogenesis, induce differentiation and growth arrest, and mediate apoptosis, contributing to normal cellular differentiation and survival pathways (Pajtler2013Expression). This receptor is also involved in immune surveillance and modulation, enhancing the immunogenicity of certain cells (Pajtler2013Expression).

## Clinical Significance
Mutations in the NTRK1 gene are primarily associated with congenital insensitivity to pain with anhidrosis (CIPA), also known as hereditary sensory and autonomic neuropathy type IV (HSAN IV). This rare autosomal recessive disorder is characterized by a lack of pain sensation, inability to sweat (anhidrosis), mental retardation, and self-mutilating behavior. The condition results from mutations that disrupt the nerve growth factor (NGF) signaling pathway, crucial for the development and function of sensory and sympathetic neurons (Tüysüz2008Novel; Verpoorten2006Novel; Mardy1999Congenital).

Various types of mutations in NTRK1, including missense, nonsense, frameshift, and splice-site mutations, have been identified in patients with CIPA. These mutations lead to defective development of small nociceptive neurons and abnormal innervation of sweat glands, resulting in the clinical symptoms of the disorder (Verpoorten2006Novel; Alberti2003RET). Some mutations, such as those affecting the tyrosine kinase domain, impair receptor processing and function, while others reduce kinase activity, leading to insufficient neuronal differentiation (Alberti2003RET).

In addition to CIPA, NTRK1 mutations have been implicated in craniofacial abnormalities, as observed in some patients, suggesting a broader role in multi-systemic development (Gao2013Oral).

## Interactions
NTRK1, also known as TrkA, is a receptor tyrosine kinase that interacts with various proteins to mediate its signaling functions. Upon binding with nerve growth factor (NGF), NTRK1 undergoes dimerization and autophosphorylation at specific tyrosine residues, creating binding sites for proteins with PTB or SH2 domains. These interactions activate several signaling pathways, including those involving Ras, Rac, PI3K, and PLC-γ, which are crucial for cellular processes such as proliferation, differentiation, and apoptosis (Pierotti2006Oncogenic; Greco2010Rearrangements).

NTRK1 interacts with proteins like SHC, GRB2, FRS2, and PLCG1, which are involved in the Ras/MAPK and PI3K signaling pathways (Pierotti2006Oncogenic). The interaction with SHC is particularly important for the oncogenic activity of TRK oncoproteins, which are derived from rearrangements involving NTRK1 (Pierotti2006Oncogenic).

In neuroblastoma, NTRK1 is associated with lipid rafts and endosomes, where it interacts with Src family kinases (SFKs) such as LYN and FYN. These interactions are crucial for its role in terminal differentiation and apoptosis, contrasting with the poor prognosis associated with NTRK2/TrkB (PalaciosMoreno2015Neuroblastoma). NTRK1 also interacts with components of the Hippo pathway, influencing the activity and localization of YAP, a transcriptional co-activator (Yang2018NTRK1).


## References


[1. (Pierotti2006Oncogenic) Marco A. Pierotti and Angela Greco. Oncogenic rearrangements of the ntrk1/ngf receptor. Cancer Letters, 232(1):90–98, January 2006. URL: http://dx.doi.org/10.1016/j.canlet.2005.07.043, doi:10.1016/j.canlet.2005.07.043. This article has 64 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.canlet.2005.07.043)

[2. (Verpoorten2006Novel) Nathalie Verpoorten, Kristl G. Claeys, Liesbet Deprez, An Jacobs, Veerle Van Gerwen, Lieven Lagae, Willem Frans Arts, Linda De Meirleir, Kathelijn Keymolen, Chantal Ceuterick-de Groote, Peter De Jonghe, Vincent Timmerman, and Eva Nelis. Novel frameshift and splice site mutations in the neurotrophic tyrosine kinase receptor type 1 gene (ntrk1) associated with hereditary sensory neuropathy type iv. Neuromuscular Disorders, 16(1):19–25, January 2006. URL: http://dx.doi.org/10.1016/j.nmd.2005.10.007, doi:10.1016/j.nmd.2005.10.007. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.nmd.2005.10.007)

[3. (Tüysüz2008Novel) Beyhan Tüysüz, Fatih Bayrakli, Michael L. DiLuna, Kaya Bilguvar, Yasar Bayri, Cengiz Yalcinkaya, Aysegul Bursali, Elif Ozdamar, Baris Korkmaz, Christopher E. Mason, Ali K. Ozturk, Richard P. Lifton, Matthew W. State, and Murat Gunel. Novel ntrk1 mutations cause hereditary sensory and autonomic neuropathy type iv: demonstration of a founder mutation in the turkish population. Neurogenetics, 9(2):119–125, March 2008. URL: http://dx.doi.org/10.1007/s10048-008-0121-9, doi:10.1007/s10048-008-0121-9. This article has 14 citations and is from a peer-reviewed journal.](https://doi.org/10.1007/s10048-008-0121-9)

[4. (Indo2001Molecular) Yasuhiro Indo. Molecular basis of congenital insensitivity to pain with anhidrosis (cipa): mutations and polymorphisms intrka (ntrk1) gene encoding the receptor tyrosine kinase for nerve growth factor. Human Mutation, 18(6):462–471, 2001. URL: http://dx.doi.org/10.1002/humu.1224, doi:10.1002/humu.1224. This article has 140 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/humu.1224)

[5. (Greco2010Rearrangements) A. Greco, C. Miranda, and M.A. Pierotti. Rearrangements of ntrk1 gene in papillary thyroid carcinoma. Molecular and Cellular Endocrinology, 321(1):44–49, May 2010. URL: http://dx.doi.org/10.1016/j.mce.2009.10.009, doi:10.1016/j.mce.2009.10.009. This article has 145 citations and is from a peer-reviewed journal.](https://doi.org/10.1016/j.mce.2009.10.009)

[6. (PalaciosMoreno2015Neuroblastoma) Juan Palacios-Moreno, Lauren Foltz, Ailan Guo, Matthew P. Stokes, Emily D. Kuehn, Lynn George, Michael Comb, and Mark L. Grimes. Neuroblastoma tyrosine kinase signaling networks involve fyn and lyn in endosomes and lipid rafts. PLOS Computational Biology, 11(4):e1004130, April 2015. URL: http://dx.doi.org/10.1371/journal.pcbi.1004130, doi:10.1371/journal.pcbi.1004130. This article has 62 citations and is from a highest quality peer-reviewed journal.](https://doi.org/10.1371/journal.pcbi.1004130)

[7. (Mardy1999Congenital) Sek Mardy, Yuichi Miura, Fumio Endo, Ichiro Matsuda, László Sztriha, Philippe Frossard, Allie Moosa, Essam A.R. Ismail, Alfons Macaya, Generoso Andria, Ennio Toscano, William Gibson, Gail E. Graham, and Yasuhiro Indo. Congenital insensitivity to pain with anhidrosis: novel mutations in the trka (ntrk1) gene encoding a high-affinity receptor for nerve growth factor. The American Journal of Human Genetics, 64(6):1570–1579, June 1999. URL: http://dx.doi.org/10.1086/302422, doi:10.1086/302422. This article has 122 citations.](https://doi.org/10.1086/302422)

[8. (Gao2013Oral) Li Gao, Hao Guo, Nan Ye, Yudi Bai, Xin Liu, Ping Yu, Yang Xue, Shufang Ma, Kewen Wei, Yan Jin, Lingying Wen, and Kun Xuan. Oral and craniofacial manifestations and two novel missense mutations of the ntrk1 gene identified in the patient with congenital insensitivity to pain with anhidrosis. PLoS ONE, 8(6):e66863, June 2013. URL: http://dx.doi.org/10.1371/journal.pone.0066863, doi:10.1371/journal.pone.0066863. This article has 28 citations and is from a peer-reviewed journal.](https://doi.org/10.1371/journal.pone.0066863)

[9. (Pajtler2013Expression) Kristian W. Pajtler, Vera Rebmann, Monika Lindemann, Johannes H. Schulte, Stefanie Schulte, Michael Stauder, Ivo Leuschner, Kurt‐Werner Schmid, Ulrike Köhl, Alexander Schramm, and Angelika Eggert. Expression of ntrk1/trka affects immunogenicity of neuroblastoma cells. International Journal of Cancer, 133(4):908–919, March 2013. URL: http://dx.doi.org/10.1002/ijc.28096, doi:10.1002/ijc.28096. This article has 17 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1002/ijc.28096)

[10. (Mardy2001Congenital) S. Mardy. Congenital insensitivity to pain with anhidrosis (cipa): effect of trka (ntrk1) missense mutations on autophosphorylation of the receptor tyrosine kinase for nerve growth factor. Human Molecular Genetics, 10(3):179–188, February 2001. URL: http://dx.doi.org/10.1093/hmg/10.3.179, doi:10.1093/hmg/10.3.179. This article has 68 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1093/hmg/10.3.179)

[11. (Martin-Zanca1989Molecular) Dionisio Martin-Zanca, Ralph Oskam, Gopa Mitra, Terry Copeland, and Mariano Barbacid. Molecular and biochemical characterization of the human trk proto-oncogene. Molecular and Cellular Biology, 9(1):24–33, January 1989. URL: http://dx.doi.org/10.1128/mcb.9.1.24-33.1989, doi:10.1128/mcb.9.1.24-33.1989. This article has 12 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1128/mcb.9.1.24-33.1989)

[12. (Yang2018NTRK1) Xinyuan Yang, He Shen, Brian Buckley, Yanmin Chen, Nuo Yang, Ashley L. Mussell, Mikhail Chernov, Lester Kobzik, Costa Frangou, Su-Xia Han, and Jianmin Zhang. Ntrk1 is a positive regulator of yap oncogenic function. Oncogene, 38(15):2778–2787, December 2018. URL: http://dx.doi.org/10.1038/s41388-018-0609-1, doi:10.1038/s41388-018-0609-1. This article has 18 citations and is from a domain leading peer-reviewed journal.](https://doi.org/10.1038/s41388-018-0609-1)

[13. (Alberti2003RET) Luisella Alberti, Cristiana Carniti, Claudia Miranda, Emanuela Roccato, and Marco A. Pierotti. Ret and ntrk1 proto‐oncogenes in human diseases. Journal of Cellular Physiology, 195(2):168–186, March 2003. URL: http://dx.doi.org/10.1002/jcp.10252, doi:10.1002/jcp.10252. This article has 120 citations and is from a peer-reviewed journal.](https://doi.org/10.1002/jcp.10252)